Print

Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial

2009-06-25

Jerusalem, Israel and Lund, Sweden, June 25, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the second pivotal Phase III clinical trial, BRAVO, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis (RRMS). BRAVO is a global clinical trial designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex®.

pdfTeva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial



Back